Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis
- PMID: 16040982
- PMCID: PMC1201264
- DOI: 10.1128/IAI.73.8.4694-4703.2005
Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis
Abstract
Neisseria meningitidis, an important cause of bacterial meningitis and septicemia worldwide, is associated with high mortality and serious sequelae. Natural immunity against meningococcal disease develops with age, but the specificity and functional activity of natural antibodies associated with protection are poorly understood. We addressed this question by using a selected subset of prevaccination sera (n = 26) with convergent or discrepant serum bactericidal activity (SBA) and infant rat protective activity (IRPA) against the serogroup B meningococcal strain 44/76-SL (B:15:P1.7,16) from Icelandic teenagers. The sera were analyzed by opsonophagocytic activity (OPA) assay, immunoblotting, immunoglobulin G (IgG) quantitation against live meningococcal cells by flow cytometry, and enzyme immunosorbent assay (EIA). High levels of SBA and OPA were reflected in distinct IgG binding to major outer membrane proteins and/or lipopolysaccharide in immunoblots. However, we could not detect any specific antibody patterns on blots that could explain IRPA. Only IgM antibody to group B capsular polysaccharide (B-PS), measured by EIA, correlated positively (r = 0.76, P < 0.001) with IRPA. Normal human sera (NHS; n = 20) from healthy Finnish children of different ages (7, 14, and 24 months and 10 years) supported this finding and showed an age-related increase in IRPA that coincided with the acquisition of B-PS specific IgM antibody. The protection was independent of complement-mediated bacterial lysis, as detected by the inability of NHS to augment SBA in the presence of human or infant rat complement and the equal protective activity of NHS in rat strains with fully functional or C6-deficient complement.
Figures






Similar articles
-
Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.Vaccine. 2005 Sep 23;23(40):4821-33. doi: 10.1016/j.vaccine.2005.05.005. Vaccine. 2005. PMID: 15970361
-
Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.Infect Immun. 2006 May;74(5):2803-8. doi: 10.1128/IAI.74.5.2803-2808.2006. Infect Immun. 2006. PMID: 16622217 Free PMC article.
-
Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England.Clin Vaccine Immunol. 2015 May;22(5):503-9. doi: 10.1128/CVI.00100-15. Epub 2015 Mar 4. Clin Vaccine Immunol. 2015. PMID: 25739917 Free PMC article.
-
Meningococcal surrogates of protection--serum bactericidal antibody activity.Vaccine. 2005 Mar 18;23(17-18):2222-7. doi: 10.1016/j.vaccine.2005.01.051. Vaccine. 2005. PMID: 15755600 Review.
-
Neisseria meningitidis serogroup B: laboratory correlates of protection.FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89-96. doi: 10.1111/j.1574-695X.2002.tb00608.x. FEMS Immunol Med Microbiol. 2002. PMID: 12381458 Review.
Cited by
-
Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents.Clin Vaccine Immunol. 2007 Jan;14(1):65-73. doi: 10.1128/CVI.00230-06. Epub 2006 Oct 25. Clin Vaccine Immunol. 2007. PMID: 17065257 Free PMC article. Clinical Trial.
-
Extracellular structure of polysialic acid explored by on cell solution NMR.Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11557-61. doi: 10.1073/pnas.0704404104. Epub 2007 Jul 3. Proc Natl Acad Sci U S A. 2007. PMID: 17609375 Free PMC article.
-
The acute-phase reactant C-reactive protein binds to phosphorylcholine-expressing Neisseria meningitidis and increases uptake by human phagocytes.Infect Immun. 2008 Mar;76(3):1298-304. doi: 10.1128/IAI.00741-07. Epub 2008 Jan 14. Infect Immun. 2008. PMID: 18195032 Free PMC article.
-
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.Infect Immun. 2009 Feb;77(2):764-9. doi: 10.1128/IAI.01191-08. Epub 2008 Dec 1. Infect Immun. 2009. PMID: 19047406 Free PMC article.
-
Septicaemia models using Streptococcus pneumoniae and Listeria monocytogenes: understanding the role of complement properdin.Med Microbiol Immunol. 2014 Aug;203(4):257-71. doi: 10.1007/s00430-013-0324-z. Epub 2014 Apr 12. Med Microbiol Immunol. 2014. PMID: 24728387 Free PMC article.
References
-
- Aase, A., G. Bjune, E. A. Høiby, E. Rosenqvist, A. K. Pedersen, and T. E. Michaelsen. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:3531-3536. - PMC - PubMed
-
- Aase, A., E. A. Høiby, and T. E. Michaelsen. 1998. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47:388-396. - PubMed
-
- Artenstein, M. S., R. Gold, J. G. Zimmerly, F. A. Wyle, H. Schneider, and C. Harkins. 1970. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:417-420. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources